Data / Form D filings / SEngine Precision Medicine, Inc.
SEngine Precision Medicine, Inc.: Form D filings
SEngine Precision Medicine, Inc., a biotechnology company in Seattle, WA, filed 3 Form D notices with the SEC between 2018 and 2023. The latest, on March 10, 2023, reports $600,000 sold of a $3.6 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 401 TERRY AVE N., Seattle, WA, 98109
- Phone
- (206) 732-2165
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1752445
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 10, 2023 | New notice | $3,577,538 | $600,000 | $2,977,538 | 2 | Feb 24, 2023 | sec.gov |
| Oct 9, 2019 | Amendment | $13,581,859 | $8,645,984 | $4,935,875 | 40 | Aug 29, 2018 | sec.gov |
| Sep 12, 2018 | New notice | $13,581,859 | $720,000 | $12,861,859 | 8 | Aug 29, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Christopher Kemp | Executive Officer, Promoter | |
| Pablo Prichard | Director | |
| Tony Hsu | Executive Officer | |
| Elliott Burkland | Director | |
| Carla Grandori | Executive Officer, Director, Promoter |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Mar 6, 2023 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what SEngine Precision Medicine, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.